XORTX Therapeutics Earnings Call Transcripts

Fiscal Year 2026

Transcript

The company is advancing a late-stage gout therapy for allopurinol-intolerant patients, targeting NDA submission within 12-14 months, and preparing to relaunch its ADPKD program. Both programs address large unmet needs, with strong clinical data, robust patent protection, and significant market potential.

Read full transcript →